News

Israel's patent law criticised

BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7133.723e (Published 07 March 1998) Cite this as: BMJ 1998;316:723
  1. Judy Siegel-Itzkovich
  1. Jerusalem

    Israel's newly amended patent law, which will allow pharmaceutical companies to develop generic versions of patented drugs before their patents expire, has aroused sharp criticism from the European Union (EU) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

    EU officials have warned that the legislation violates patent rights and international treaties to which Israel is a signatory. US patent lawyer Richard …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe